You are here

  • Home
  • Archive
  • Volume 78, Issue 8
  • Association of MUC5B promoter polymorphism with interstitial lung disease in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis

Article Text

Article menu
Download PDFPDF
Letter
Association of MUC5B promoter polymorphism with interstitial lung disease in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis
  1. Natsumi Namba1,2,
  2. Aya Kawasaki1,
  3. Ken-ei Sada3,
  4. Fumio Hirano4,5,
  5. Shigeto Kobayashi6,
  6. Hidehiro Yamada7,
  7. Hiroshi Furukawa1,8,
  8. Kota Shimada8,9,
  9. Atsushi Hashimoto8,
  10. Toshihiro Matsui8,
  11. Kenji Nagasaka10,
  12. Takahiko Sugihara11,
  13. Aika Suzuki12,
  14. Kunihiro Yamagata13,
  15. Takayuki Sumida14,
  16. Shigeto Tohma8,15,
  17. Sakae Homma12,
  18. Shoichi Ozaki7,
  19. Hiroshi Hashimoto16,
  20. Hirofumi Makino17,
  21. Yoshihiro Arimura18,
  22. Masayoshi Harigai19,
  23. Naoyuki Tsuchiya1
  24. On behalf of Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS)
  1. 1 Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
  2. 2 School of Medical Sciences, University of Tsukuba, Tsukuba, Japan
  3. 3 Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
  4. 4 Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
  5. 5 Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
  6. 6 Department of Internal Medicine, Juntendo University Koshigaya Hospital, Koshigaya, Japan
  7. 7 Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
  8. 8 Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan
  9. 9 Department of Rheumatology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan
  10. 10 Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan
  11. 11 Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan
  12. 12 Department of Respiratory Medicine, Toho University Graduate School of Medicine, Tokyo, Japan
  13. 13 Department of Nephrology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
  14. 14 Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
  15. 15 President, National Hospital Organization Tokyo National Hospital, Kiyose, Japan
  16. 16 School of Medicine, Juntendo University, Tokyo, Japan
  17. 17 President, Okayama University, Okayama, Japan
  18. 18 Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan
  19. 19 Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Department of Rheumatology, School of Medicine, Tokyo Women's Medical University, Tokyo, Japan
  1. Correspondence to Dr Aya Kawasaki, Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan; a-kawasaki{at}umin.net; Naoyuki Tsuchiya, Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan; tsuchiya-tky{at}umin.net

  • Present affiliation The present affiliation of Hidehiro Yamada is: Centre for Rheumatic Diseases, Seirei Yokohama Hospital, Yokohama, Japan

https://doi.org/10.1136/annrheumdis-2018-214263

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Interstitial lung disease (ILD) is a major complication and a prognostic factor of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).1 The prevalence of ILD is higher in Japanese AAV as compared with European populations.1 In a Japanese inception cohort study, 45.0% of patients with microscopic polyangiitis (MPA) were complicated by ILD.2 Such ethnic difference suggests a role for genetic background in the development of AAV-associated ILD (AAV-ILD).

    Single nucleotide polymorphism (SNP) rs35705950(G/T) in the promotor region of MUC5B, encoding mucin 5B, is a strong genetic factor for idiopathic pulmonary fibrosis (IPF). The risk allele T was associated with overexpression of mucin 5B in the lung.3 Recently, rs35705950 has been associated with rheumatoid arthritis-associated ILD (RA-ILD).4

    Here, we examined whether rs35705950 is associated with AAV-ILD in case-control and case–case association studies. About 474 Japanese patients with AAV and 842 healthy Japanese controls were recruited at rheumatology or nephrology centres based on the clinical diagnosis of AAV, and classified according to the European Medicines Agency algorithm.5 The patients were examined for the presence or absence of ILD using CT or high-resolution CT (HRCT) by site investigators. 163 patients were reported positive and 264 negative for ILD (see online supplementary table S1,S2). This study was conducted in accordance with the Declaration of Helsinki.

    Supplemental material

    [annrheumdis-2018-214263supp001.htm]

    Genotyping was performed using TaqMan SNP Genotyping Assays (Assay ID: C___1582254_20) (Thermo Fisher Scientific, Waltham, Massachusetts, USA). Odds ratios (ORs), 95% confidence intervals …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Contributors NN, AK, NT: conceived and designed the study, performed genotyping and statistical analysis, interpreted the data and wrote the manuscript. K-eS, FH, SK, HY, HF, KS, AH, TM, KN, TSug, KY, TSum, ST: recruited patients and analysed clinical data. AS, SH: centrally evaluated HRCT images. SO, HH, HM, YA, MH: organised study groups, conceived the study and interpreted the data. All authors read and approved the manuscript.

    • Funding This study was supported by the grants from the Japan Agency for Medical Research and Development "The Study Group for Strategic Exploration of Drug Seeds for ANCA Associated Vasculitis and Construction of Clinical Evidence (grant number 17ek0109104h0003)”, ”The Strategic Study Group to Establish the Evidence for Intractable Vasculitis Guideline (grant number 17ek0109121h0003)” and “Multitiered study to address clinical questions for management of intractable vasculitides (grant number 18ek0109360h001)", and an award grant from Japan College of Rheumatology.

    • Competing interests FH is employed by The Department of Lifetime Clinical Immunology of Tokyo Medical and Dental University (TMDU), which has received unrestricted research grants from Chugai Pharmaceutical Co, Ltd. Ono Pharmaceuticals; Mitsubishi Tanabe Pharma Co. UCB Japan; CSL Behring; Towa Pharmaceutical Co, Ltd. Abbvie Japan Co, Ltd. Japan Blood Products Organization; Ayumi Pharmaceutical Co; and Nippon Kayaku Co, Ltd, with which TMDU currently pays the salary of FH. FH has also received speaking fees from Ono Pharmaceuticals, Astellas Pharma Inc. Sumitomo Dainippon Pharma and Chugai Pharmaceutical Co, Ltd. KS has received lecture fee from Chugai. HF has the following conflicts, and the following funders are supported wholly or in part by the indicated pharmaceutical companies. The Japan Research Foundation for Clinical Pharmacology is run by Daiichi Sankyo, the Takeda Science Foundation is supported by an endowment from Takeda Pharmaceutical Company and the Nakatomi Foundation was established by Hisamitsu Pharmaceutical Co, Inc. The Daiwa Securities Health Foundation was established by Daiwa Securities Group Inc. and Mitsui Sumitomo Insurance Welfare Foundation was established by Mitsui Sumitomo Insurance Co, Ltd. HF was supported by research grants from Bristol-Myers Squibb Co. HF received honoraria from Ajinomoto Co, Inc., Daiichi Sankyo Co., Ltd., Dainippon Sumitomo Pharma Co, Ltd. Pfizer Japan Inc, and Takeda Pharmaceutical Company, Luminex Japan Corporation Ltd, and Ayumi Pharmaceutical Corporation. ST was supported by research grants from Abbott Japan Co, Ltd, Astellas Pharma Inc, Chugai Pharmaceutical Co, Ltd. Eisai Co, Ltd, Mitsubishi Tanabe Pharma Corporation, Merck Sharp and Dohme Inc. Pfizer Japan Inc, Takeda Pharmaceutical Company Limited and Teijin Pharma Limited. TSug has received honoraria from Chugai Pharmaceutical Co, Ltd. Takeda Pharmaceutical Co. Ltd, Mitsubishi-Tanabe Pharma Co, Astellas Pharma Inc, Bristol Myers Squibb K.K. Pfizer Japan Inc, UCB Japan Co. Ltd, and Abbvie Japan Co, Ltd, and has received research grant support from Takeda Pharmaceutical Co, Ltd, Astellas Pharma Inc, and Teijin Pharma Ltd. AH has received research funding from Chugai Pharmaceutical Co, Ltd. HM is a consultant for AbbVie and Teijin, receives speaker honoraria from Boehringer-Ingelheim. MH has received research grants and/or honoraria from Abbott Japan Co, Ltd. Astellas Pharma Inc; Bristol-Myers Squibb K.K. Chugai Pharmaceutical Co, Ltd. Eisai Co, Ltd. Janssen Pharmaceutical K.K. Mitsubishi Tanabe Pharma Co; Santen Pharmaceutical Co; Ltd. Takeda Pharmaceutical Co, Ltd. Teijin Pharma, Ltd. and Pfizer Japan Inc. NT has received 2015 Japan College of Rheumatology Award from Japan College of Rheumatology and 2017 Novartis Rheumatology Award from Japan Rheumatism Association with research fundings, and speaker’s honoraria from Ayumi Pharmaceutical Corporation.

    • Patient consent for publication Not required.

    • Ethics approval The study protocol was reviewed and approved by the Ethics Committees of University of Tsukuba, Tokyo Women’s Medical University, Tokyo Medical and Dental University, National Hospital Organization Sagamihara Hospital, Okayama University, and all the institutes involved in the recruitment of subjects.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data sharing statement All data are presented in the paper and in the supplementary material.